Please ensure Javascript is enabled for purposes of website accessibility

The FDA and FTC Announce an Effort to Deter Anti-Competitive Practices Among Drugmakers

By Mark Prvulovic – Updated Feb 3, 2020 at 7:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Regulators are trying their best to help encourage competition, particularly in the biosimilars market.

The Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) made a joint announcement on Monday about their plan to tackle anticompetitive practices among the major drugmakers. The agencies are trying to encourage more competition to hopefully help lower drug prices.

The announcement specifically addresses a class of drugs known as biosimilars, which are similar to generic drugs in that they are cheaper than exclusive, patented drugs already on the market. Unlike generic drugs, which are identical to the already approved drugs they compete with, biosimilars are not exact copies but are similar enough that they produce almost the same effect.

Packets of generic pharmaceutical pills.

Image source: Getty Images.

"Competition is key for helping American patients have access to affordable medicines," said Stephen M. Hahn, FDA commissioner, in the agency's press release. "Strengthening efforts to curtail and discourage anticompetitive behavior is key for facilitating robust competition for patients in the biologics marketplace, including through biosimilars, bringing down the costs of these crucial products for patients."

An ongoing issue

Rising drug costs have been a major problem in the U.S., with political candidates as well as regulators promising to help tackle this issue. Helping encourage competition among drugmakers, especially in the realm of generic drugs and biosimilars, is seen as one way to help lower drug prices.

Major pharmaceutical giants have been accused of stifling competition before. Mylan (MYL), Novartis (NVS -0.51%), and Teva Pharmaceuticals (TEVA -2.31%) were all implicated by state prosecutors last year for inflating the prices of generic drugs in an elaborate price-fixing scheme, and in some cases, inflating prices by as much as 1,000%, according to case officials. At the moment, litigation is still ongoing, with Teva and other implicated drugmakers considering a possible settlement with federal prosecutors. 

Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teva Pharmaceutical Industries Stock Quote
Teva Pharmaceutical Industries
TEVA
$8.46 (-2.31%) $0.20
Novartis AG Stock Quote
Novartis AG
NVS
$75.65 (-0.51%) $0.39
Mylan Stock Quote
Mylan
MYL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
338%
 
S&P 500 Returns
108%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.